AML patients were classified into 4 groups where patients with (FLT3/ITD –ve, NPM1 –ve) and (FLT/ITD3–ve, NPM1 +ve) had higher OS rates than patients with (FLT3/ITD +ve, NPM1 -ve) and (FLT3/ITD +ve, NPM1 +ve) with p-value < 0.001 (Figure 1). This evidence concerns the gene FLT3 and acute myeloid leukemia.